Chemoradiotherapy for Advanced Esophageal Cancer

This study aims to show that the addition of carboplatin and paclitaxel chemotherapy to a palliative course of external beam radiation treatment improves both dysphagia relief and patient quality of life in patients with unresectable esophageal cancer.

Trial Details

NCT ID
NCT02297217
Phase
PHASE2
Sponsor
AHS Cancer Control Alberta
Status
RECRUITING
Cancer Type
Esophageal Cancer
Interventions
  • Carboplatin and Taxol (paclitaxel)
  • External Beam Radiation
Locations (sample)
  • Calgary, Alberta, Canada|51.05011,-114.08529

Key Eligibility Criteria

  • Biopsy proven carcinoma of the esophagus.
  • Not a candidate for radical/curative treatment due to the advanced nature of the disease, presence of metastases, or intercurrent illness.
  • Symptomatic patients with Mellow Dysphagia Scores of ≥ 1 i.e. able to eat only some solids.
  • ECOG Performance status ≤ 2.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Esophageal Cancer Trials on Trialify →